\-\ Texto\\:\\ \ \(0\)\
\-\ scars\\ on\\ abdomen\\ from\\ previous\\ surgeries\\.\\ physical\\ exam\\ is\\ otherwise\\ unremarkable\\.\ \(0\)\
\-\ patient\\ treated\\ with\\ xelox\\ \\[capecitabine\\ plus\\ oxiliplatin\\]chemotherapy\\.\\ repeat\\ imaging\\ has\\ showed\\ modest\\ decrease\\ in\\ the\\ size\\ of\\ his\\ hepatic\\ lesion\\.\\ typically\\ patients\\ with\\ metastases\\ this\\ advanced\\ have\\ very\\ poor\\ prognosis\\.\ \(0\)\
\-\ the\\ first\\ image\\ shows\\ a\\ 1\\ x\\ 1\\ cm\\ area\\ of\\ hypoattnuation\\ in\\ the\\ left\\ lobe\\ of\\ the\\ liver\\.\\ this\\ was\\ the\\ image\\ taken\\ when\\ the\\ patient\\ presented\\ with\\ his\\ abdominal\\ complaints\\.\\ his\\ symptoms\\ resolved\\ and\\ he\\ failed\\ to\\ follow\\ up\\.\\ the\\ second\\ and\\ third\\ images\\ are\\ from\\ a\\ year\\ later\\.\\ they\\ show\\ a\\ left\\ hepatic\\ lobe\\ mass\\ that\\ has\\ diminished\\ attenuation\\ and\\ heterogeneous\\ enhancement\\.\\ \\ the\\ mass\\ measures\\ approximately\\ 4\\ x\\ 4cm\\ and\\ there\\ is\\ intrahepatic\\ ductal\\ dilatation\\ distal\\ to\\ the\\ mass\\ lesion\ \(0\)\
\-\ metastatic\\ colon\\ cancer\ \(1\)\
\-\ 1\\.\\ metastatic\\ colon\\ cancer\ \(0\)\
\-\ 2\\.\\ primary\\ cholangiocarcinoma\\,\\ or\\ hepatocellular\\ carcinoma\ \(0\)\
\-\ 3\\.\\ benign\\ hepatoma\ \(0\)\
\-\ 69\\ year\\ old\\ male\\ with\\ remote\\ history\\ of\\ colon\\ cancer\\ status\\ post\\ total\\ colectomy\\ 9\\ years\\ ago\\ presents\\ with\\ unintentional\\ weight\\ loss\\ and\\ vague\\ abdominal\\ pain\\.\\ patient\\ currently\\ smokes\\ 1\\/2\\ pack\\/day\\.\ \(0\)\
\-\ past\\ medical\\ history\\ notable\\ for\\:\ \(0\)\
\-\ diabetes\\ mellitus\\ type\\ 2\\,\ \(1\)\
\-\ hypertension\\,\ \(74\)\
\-\ atrial\\ fibrillation\ \(35\)\
\-\ this\\ case\\ brings\\ to\\ light\\ the\\ utility\\ of\\ ct\\ in\\ the\\ post\\ operative\\ period\\ as\\ a\\ method\\ of\\ surveillance\\ for\\ recurrence\\ and\\ or\\ metastases\\ of\\ a\\ primary\\ colon\\ cancer\\.\\ in\\ 2005\\,\\ the\\ american\\ society\\ of\\ clinical\\ oncology\\ \\[asca\\]\\ updated\\ their\\ post\\ resection\\ surveillance\\ recommendations\\ to\\ include\\ yearly\\ ct\\ for\\ patients\\ who\\ had\\ stage\\ ii\\ or\\ worse\\ disease\\.\\ they\\ had\\ previously\\ recommended\\ against\\ ct\\ monitoring\\ but\\ unanimously\\ changed\\ their\\ recommendation\\ after\\ 3\\ meta\\-analyses\\ all\\ showed\\ significant\\ decrease\\ in\\ mortality\\ when\\ post\\ op\\ ct\\ surveillance\\ was\\ done\\.\\ the\\ decrease\\ was\\ due\\ to\\ early\\ identification\\ of\\ resectable\\ hepatic\\ metastases\\!\ \(0\)\
\-\ asca\\ recommended\\ a\\ surveillance\\ period\\ of\\ 3\\ years\\ based\\ on\\ the\\ average\\ length\\ of\\ the\\ meta\\-analyses\\.\\ given\\ that\\ our\\ patient\\ was\\ 9\\ years\\ post\\ resection\\,\\ these\\ guidelines\\ would\\ not\\ have\\ affected\\ his\\ outcome\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ surveillance\\:\\ 0\\.06239308929618789\ \(0\)\
\-\ asca\\:\\ 0\\.051703920375170076\ \(0\)\
\-\ meta\\-analyses\\:\\ 0\\.051703920375170076\ \(0\)\
\-\ post\\:\\ 0\\.039455059135957385\ \(0\)\
\-\ colon\\:\\ 0\\.039365781933399874\ \(0\)\
\-\ decrease\\:\\ 0\\.03440097048851674\ \(0\)\
\-\ cancer\\:\\ 0\\.032952085212489914\ \(0\)\
\-\ metastases\\:\\ 0\\.03211788079216702\ \(0\)\
\-\ hepatic\\:\\ 0\\.03139437846163647\ \(0\)\
\-\ his\\:\\ 0\\.028890193872691285\ \(0\)\
\-\ \\]\\:\\ 0\\.026227055730866946\ \(0\)\
\-\ \\[\\:\\ 0\\.026151375937107958\ \(0\)\
\-\ xelox\\:\\ 0\\.025851960187585038\ \(0\)\
\-\ capecitabine\\:\\ 0\\.025851960187585038\ \(0\)\
\-\ oxiliplatin\\:\\ 0\\.025851960187585038\ \(0\)\
\-\ hypoattnuation\\:\\ 0\\.025851960187585038\ \(0\)\
\-\ unanimously\\:\\ 0\\.025851960187585038\ \(0\)\
\-\ pack\\/day\\:\\ 0\\.023819270508523616\ \(0\)\
\-\ period\\:\\ 0\\.023432474242589214\ \(0\)\
\-\ years\\:\\ 0\\.022075452818344422\ \(0\)\
\-\ their\\:\\ 0\\.02193750503655526\ \(0\)\
\-\ modest\\:\\ 0\\.021132200913584743\ \(0\)\
\-\ recommended\\:\\ 0\\.020777236747230213\ \(0\)\
\-\ 9\\:\\ 0\\.02071738824180944\ \(0\)\
\-\ hepatoma\\:\\ 0\\.02014547881205626\ \(0\)\
\-\ smokes\\:\\ 0\\.02014547881205626\ \(0\)\
\-\ resectable\\:\\ 0\\.02014547881205626\ \(0\)\
\-\ brings\\:\\ 0\\.019753891150400767\ \(0\)\
\-\ unintentional\\:\\ 0\\.018820009240962252\ \(0\)\
\-\ utility\\:\\ 0\\.018330114564530677\ \(0\)\
\-\ updated\\:\\ 0\\.018330114564530677\ \(0\)\
\-\ they\\:\\ 0\\.018058335052711472\ \(0\)\
\-\ society\\:\\ 0\\.017910463996669467\ \(0\)\
\-\ plus\\:\\ 0\\.017721201471339345\ \(0\)\
\-\ colectomy\\:\\ 0\\.017543416656628393\ \(0\)\
\-\ recommendation\\:\\ 0\\.017543416656628393\ \(0\)\
\-\ guidelines\\:\\ 0\\.017543416656628393\ \(0\)\
\-\ 1\\/2\\:\\ 0\\.01692374189514098\ \(0\)\
\-\ yearly\\:\\ 0\\.01692374189514098\ \(0\)\
\-\ op\\:\\ 0\\.01692374189514098\ \(0\)\
\-\ scars\\:\\ 0\\.016787319561900826\ \(0\)\
\-\ \\!\\:\\ 0\\.016787319561900826\ \(0\)\
\-\ recommendations\\:\\ 0\\.016656962486913045\ \(0\)\
\-\ x\\:\\ 0\\.01653411340379752\ \(0\)\
\-\ showed\\:\\ 0\\.016432863741487957\ \(0\)\
\-\ 4cm\\:\\ 0\\.016186749436839207\ \(0\)\
\-\ oncology\\:\\ 0\\.01597719235771268\ \(0\)\
\-\ fibrillation\\:\\ 0\\.01587777431760804\ \(0\)\
\-\ changed\\:\\ 0\\.01587777431760804\ \(0\)\
\-\ cholangiocarcinoma\\:\\ 0\\.015781616479417455\ \(0\)\
\-\ 69\\:\\ 0\\.015781616479417455\ \(0\)\
\-\ mellitus\\:\\ 0\\.015781616479417455\ \(0\)\
\-\ identification\\:\\ 0\\.015781616479417455\ \(0\)\
\-\ image\\:\\ 0\\.015655068424032848\ \(0\)\
\-\ resection\\:\\ 0\\.015630003844693364\ \(0\)\
\-\ method\\:\\ 0\\.015598272324046973\ \(0\)\
\-\ outcome\\:\\ 0\\.014961719522763022\ \(0\)\
\-\ surgeries\\:\\ 0\\.014891052216079559\ \(0\)\
\-\ primary\\:\\ 0\\.014846828521382383\ \(0\)\
\-\ intrahepatic\\:\\ 0\\.014754629882839404\ \(0\)\
\-\ average\\:\\ 0\\.014624272807851623\ \(0\)\
\-\ remote\\:\\ 0\\.01449946455442407\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.014438997436527483\ \(0\)\
\-\ when\\:\\ 0\\.01435384890097364\ \(0\)\
\-\ against\\:\\ 0\\.01404740977487199\ \(0\)\
\-\ ct\\:\\ 0\\.014021157224540092\ \(0\)\
\-\ failed\\:\\ 0\\.01399550485669193\ \(0\)\
\-\ notable\\:\\ 0\\.01384508463854662\ \(0\)\
\-\ monitoring\\:\\ 0\\.01384508463854662\ \(0\)\
\-\ diminished\\:\\ 0\\.013702004978225706\ \(0\)\
\-\ mortality\\:\\ 0\\.013655822113216498\ \(0\)\
\-\ operative\\:\\ 0\\.013521483297875463\ \(0\)\
\-\ 2005\\:\\ 0\\.013521483297875463\ \(0\)\
\-\ lobe\\:\\ 0\\.013485779166706945\ \(0\)\
\-\ vague\\:\\ 0\\.013478037298505547\ \(0\)\
\-\ patients\\:\\ 0\\.012971112019742086\ \(0\)\
\-\ advanced\\:\\ 0\\.012823657382628098\ \(0\)\
\-\ atrial\\:\\ 0\\.012823657382628098\ \(0\)\
\-\ metastatic\\:\\ 0\\.01261647744056358\ \(0\)\
\-\ length\\:\\ 0\\.012559879562502176\ \(0\)\
\-\ abdominal\\:\\ 0\\.01252738556083352\ \(0\)\
\-\ diabetes\\:\\ 0\\.012406307757466059\ \(0\)\
\-\ resolved\\:\\ 0\\.01214864982259411\ \(0\)\
\-\ american\\:\\ 0\\.01193720321291275\ \(0\)\
\-\ 1\\:\\ 0\\.011925667847271008\ \(0\)\
\-\ our\\:\\ 0\\.011911812999589835\ \(0\)\
\-\ prognosis\\:\\ 0\\.011886640730700122\ \(0\)\
\-\ ductal\\:\\ 0\\.011812394959485198\ \(0\)\
\-\ repeat\\:\\ 0\\.011788058294339463\ \(0\)\
\-\ 3\\:\\ 0\\.011735926842853605\ \(0\)\
\-\ light\\:\\ 0\\.011692682365584156\ \(0\)\
\-\ was\\:\\ 0\\.011592698207785182\ \(0\)\
\-\ poor\\:\\ 0\\.01127772763750879\ \(0\)\
\-\ worse\\:\\ 0\\.011099942822797838\ \(0\)\
\-\ recurrence\\:\\ 0\\.010932322840862506\ \(0\)\
\-\ complaints\\:\\ 0\\.01087851305004668\ \(0\)\
\-\ have\\:\\ 0\\.010853009257273265\ \(0\)\
\-\ affected\\:\\ 0\\.010843180679031506\ \(0\)\
\-\ had\\:\\ 0\\.010814368441294476\ \(0\)\
\-\ ii\\:\\ 0\\.01080826894147632\ \(0\)\
\-\ total\\:\\ 0\\.010790967703566676\ \(0\)\
\-\ dilatation\\:\\ 0\\.010739668121609147\ \(0\)\
\-\ measures\\:\\ 0\\.01072276576173598\ \(0\)\
\-\ stage\\:\\ 0\\.01068925052471656\ \(0\)\
\-\ previously\\:\\ 0\\.010527189883440754\ \(0\)\
\-\ mass\\:\\ 0\\.01045566868282315\ \(0\)\
\-\ taken\\:\\ 0\\.010449398815014277\ \(0\)\
\-\ done\\:\\ 0\\.010388618373615106\ \(0\)\
\-\ lesion\\:\\ 0\\.010208535049856039\ \(0\)\
\-\ attenuation\\:\\ 0\\.010075135103888676\ \(0\)\
\-\ third\\:\\ 0\\.010048230774633423\ \(0\)\
\-\ patient\\:\\ 0\\.01004799918963505\ \(0\)\
\-\ currently\\:\\ 0\\.009930125498569083\ \(0\)\
\-\ hypertension\\:\\ 0\\.009879123320528411\ \(0\)\
\-\ previous\\:\\ 0\\.00973123225417389\ \(0\)\
\-\ second\\:\\ 0\\.009625011540290258\ \(0\)\
\-\ based\\:\\ 0\\.0095562767221905\ \(0\)\
\-\ has\\:\\ 0\\.009411730032224504\ \(0\)\
\-\ ago\\:\\ 0\\.009327650500871696\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.009214648553651042\ \(0\)\
\-\ early\\:\\ 0\\.009164689060535008\ \(0\)\
\-\ very\\:\\ 0\\.009096145508671933\ \(0\)\
\-\ later\\:\\ 0\\.009048148507310626\ \(0\)\
\-\ otherwise\\:\\ 0\\.009000924438200424\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.00898224570422541\ \(0\)\
\-\ weight\\:\\ 0\\.00898224570422541\ \(0\)\
\-\ status\\:\\ 0\\.008945241411089893\ \(0\)\
\-\ would\\:\\ 0\\.008917791432322844\ \(0\)\
\-\ typically\\:\\ 0\\.008845823370985256\ \(0\)\
\-\ or\\:\\ 0\\.008811050577393321\ \(0\)\
\-\ that\\:\\ 0\\.008656778466620664\ \(0\)\
\-\ benign\\:\\ 0\\.00864824154555191\ \(0\)\
\-\ liver\\:\\ 0\\.008639945779568104\ \(0\)\
\-\ given\\:\\ 0\\.008590658042569919\ \(0\)\
\-\ 3\\.\\:\\ 0\\.00857441117929832\ \(0\)\
\-\ this\\:\\ 0\\.008455752609801758\ \(0\)\
\-\ type\\:\\ 0\\.008447578382249004\ \(0\)\
\-\ first\\:\\ 0\\.008409042330750299\ \(0\)\
\-\ size\\:\\ 0\\.008401395517239799\ \(0\)\
\-\ unremarkable\\:\\ 0\\.008296382459478184\ \(0\)\
\-\ 2\\.\\:\\ 0\\.00796904440410633\ \(0\)\
\-\ follow\\:\\ 0\\.007962461794564323\ \(0\)\
\-\ past\\:\\ 0\\.007962461794564323\ \(0\)\
\-\ area\\:\\ 0\\.007923273443208995\ \(0\)\
\-\ 1\\.\\:\\ 0\\.007827534212016424\ \(0\)\
\-\ approximately\\:\\ 0\\.00775313145617473\ \(0\)\
\-\ medical\\:\\ 0\\.007710585923947227\ \(0\)\
\-\ clinical\\:\\ 0\\.007710585923947227\ \(0\)\
\-\ show\\:\\ 0\\.007692539397336147\ \(0\)\
\-\ treated\\:\\ 0\\.007501028844820701\ \(0\)\
\-\ from\\:\\ 0\\.00742777544371972\ \(0\)\
\-\ abdomen\\:\\ 0\\.007423414260691191\ \(0\)\
\-\ loss\\:\\ 0\\.00727408848231214\ \(0\)\
\-\ carcinoma\\:\\ 0\\.007102427184797262\ \(0\)\
\-\ all\\:\\ 0\\.007087752168420208\ \(0\)\
\-\ include\\:\\ 0\\.007029775624722248\ \(0\)\
\-\ he\\:\\ 0\\.006991751736167212\ \(0\)\
\-\ 4\\:\\ 0\\.006982322302577846\ \(0\)\
\-\ a\\:\\ 0\\.006978295633171871\ \(0\)\
\-\ history\\:\\ 0\\.006922079400041545\ \(0\)\
\-\ shows\\:\\ 0\\.006889658943486448\ \(0\)\
\-\ presented\\:\\ 0\\.006830960806517329\ \(0\)\
\-\ distal\\:\\ 0\\.006813133691923832\ \(0\)\
\-\ up\\:\\ 0\\.0067385546951736755\ \(0\)\
\-\ significant\\:\\ 0\\.0067385546951736755\ \(0\)\
\-\ cm\\:\\ 0\\.006721278937879724\ \(0\)\
\-\ enhancement\\:\\ 0\\.006716975853733243\ \(0\)\
\-\ due\\:\\ 0\\.006687029774055248\ \(0\)\
\-\ who\\:\\ 0\\.006533631698362762\ \(0\)\
\-\ these\\:\\ 0\\.0065215386860933726\ \(0\)\
\-\ for\\:\\ 0\\.006414441190405119\ \(0\)\
\-\ to\\:\\ 0\\.006261995724970474\ \(0\)\
\-\ symptoms\\:\\ 0\\.0062453298442760674\ \(0\)\
\-\ in\\:\\ 0\\.006178845016719281\ \(0\)\
\-\ physical\\:\\ 0\\.006148109294959643\ \(0\)\
\-\ the\\:\\ 0\\.006081346834470343\ \(0\)\
\-\ imaging\\:\\ 0\\.005871184235940184\ \(0\)\
\-\ left\\:\\ 0\\.005607655538257564\ \(0\)\
\-\ year\\:\\ 0\\.005607655538257564\ \(0\)\
\-\ exam\\:\\ 0\\.005505084867887209\ \(0\)\
\-\ case\\:\\ 0\\.005482417691692876\ \(0\)\
\-\ 2\\:\\ 0\\.0053962008695323934\ \(0\)\
\-\ but\\:\\ 0\\.005344584460508908\ \(0\)\
\-\ after\\:\\ 0\\.005184754259851034\ \(0\)\
\-\ presents\\:\\ 0\\.005119191482427935\ \(0\)\
\-\ images\\:\\ 0\\.0048072254895875485\ \(0\)\
\-\ male\\:\\ 0\\.004531394539259452\ \(0\)\
\-\ on\\:\\ 0\\.004245695087187262\ \(0\)\
\-\ disease\\:\\ 0\\.004096004519694147\ \(0\)\
\-\ \\,\\:\\ 0\\.003969355799373716\ \(0\)\
\-\ as\\:\\ 0\\.003790549870657266\ \(0\)\
\-\ of\\:\\ 0\\.003758187122515756\ \(0\)\
\-\ there\\:\\ 0\\.0037293711333284125\ \(0\)\
\-\ not\\:\\ 0\\.003621169125342919\ \(0\)\
\-\ are\\:\\ 0\\.003416052412110269\ \(0\)\
\-\ \\:\\:\\ 0\\.0033145889031984312\ \(0\)\
\-\ is\\:\\ 0\\.003297893128356162\ \(0\)\
\-\ and\\:\\ 0\\.003167313883851351\ \(0\)\
\-\ pain\\:\\ 0\\.003060434508887785\ \(0\)\
\-\ old\\:\\ 0\\.002565790606634178\ \(0\)\
\-\ \\.\\:\\ 0\\.0017697715942958552\ \(0\)\
\-\ with\\:\\ 0\\.0017156037549837205\ \(0\)\
